FDA Established Quantitative Medicine Center of Excellence

The new body will coordinate regulatory science efforts across the Center for Drug Evaluation and Research.

Updated on Oct. 5, 2026 in Mathematics

Bold flat-color editorial illustration showing a balanced laboratory scale with a geometric molecular model, representing standardized regulatory science. — The FDA's Center for Drug Evaluation and Research has launched the Quantitative Medicine Center of Excellence to standardize statistical and mathematical policy for drug development. AI Illustration. Upload story photo >

Live Poll

Should government drug regulators centralize their scientific coordination to improve how new medicines are developed?

The Center for Drug Evaluation and Research (CDER) has established the Quantitative Medicine Center of Excellence. The unit acts as a centralized body to coordinate quantitative medicine strategies and regulatory policy across the agency's various offices.

Why it matters

The center aims to increase operational efficiency by maximizing synergies across CDER and strengthening collaborative outreach on drug development policies. It represents a structured move to standardize how quantitative evidence is applied to regulatory decision-making.

The center focuses on three pillars: Applied Regulatory Science, Enterprise Planning and Coordination, and Education and Ecosystem Development. These areas serve to harmonize the application of quantitative methods throughout the drug development pipeline.

The players

Center for Drug Evaluation and Research

The FDA division responsible for evaluating new and generic drugs before they can be marketed in the United States.

The details

The center functions as a cooperative, coordinating body designed to align CDER-wide enterprise efforts. It operates by facilitating consistent internal and external policy development, ensuring that mathematical and statistical methodologies are applied uniformly across drug reviews. The center is also tasked with fostering a broader ecosystem for quantitative medicine through coordinated outreach and educational initiatives.

2025: The center published a Progress and Priorities Report.

The Tech Race

The formation of this center reflects a broader trend toward centralizing regulatory data analysis within federal agencies. It follows a multi-year effort to integrate quantitative medicine more deeply into standard review workflows.

For pharmaceutical developers and researchers, the center provides a clearer point of coordination for regulatory policy and quantitative standards. While the center does not change clinical trial requirements immediately, it will dictate the framework for future submissions.

The takeaway

The center marks a transition from fragmented departmental data practices to a unified, agency-wide regulatory methodology. Observers should track subsequent updates to the 2025 Progress and Priorities Report to identify shifts in formal regulatory guidance.